^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of:...Epithelial ovarian, fallopian tube, or primary peritoneal cancer:...in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection…in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinumsensitive recurrent disease.
Secondary therapy:
carboplatin + paclitaxel; carboplatin + gemcitabine
Source:
Excerpt:
Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
Secondary therapy:
carboplatin + gemcitabine
Source:
Excerpt:
Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer
Secondary therapy:
carboplatin + paclitaxel
Source:
Excerpt:
Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of:...Epithelial ovarian, fallopian tube, or primary peritoneal cancer:...in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
Secondary therapy:
bisphosphonate bound paclitaxel; pegylated liposomal doxorubicin; topotecan
Source:
Excerpt:
Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
Secondary therapy:
paclitaxel; topotecan; pegylated liposomal doxorubicin
Source:
Excerpt:
Acceptable Recurrence Therapies for…Peritoneal Cancer: Targeted Therapy...Bevacizumab.
Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC)/Fallopian Tube/Primary Peritoneal Cancer....Recurrence Therapy for Platinum-Resistant Disease….Other Recommended Regimens...Gemcitabine/bevacizumab.
Primary Systemic Therapy Regimens - Epithelial Ovarian/Fallopian Tube/Primary Peritoneal….Useful in Certain Circumstances...Docetaxel/oxaliplatin/bevacizumab + maintenance bevacizumab (for stage IB/IC).
Secondary therapy:
gemcitabine; docetaxel + oxaliplatin
Source:
Excerpt:
Peritoneal Cancer: Preferred Regimen…Paclitaxel/Carboplatin/Bevacizumab...FU/Leucovorin/Oxaliplatin ±
Bevacizumab...Capecitabine/Oxaliplatin ± Bevacizumab...Carboplatin/Gemcitabine ± Bevacizumab...Carboplatin/Liposomal Doxorubicin ± Bevacizumab...Cyclophosphamide (oral)/Bevacizumab...Liposomal Doxorubicin/Bevacizumab...Paclitaxel (weekly)/Bevacizumab...Topotecan/Bevacizumab
Secondary therapy:
topotecan; 5-fluorouracil + oxaliplatin + leucovorin calcium; cyclophosphamide; carboplatin + paclitaxel; carboplatin + doxorubicin liposomal; capecitabine + oxaliplatin; paclitaxel; doxorubicin liposomal; carboplatin + gemcitabine
